Skip to Content
Søg Menu

ASH 2023: Oral Decitabine-Cedazuridine Tablet Shows Promise for AML Treatment in Phase III Study

A phase III study unveils that an oral fixed-dose combination of decitabine and cedazuridine, offers a new, effective oral treatment route for AML patients unable to undergo standard chemotherapy.

Få adgang

Hvis du er læge, sygeplejerske eller anden sundhedsprofessionel kan du få adgang til hele artiklen ved at oprette en profil på BestPractice Nordic.

Relateret indhold

Hans Beier Ommen

ASH 2024: Nyt om AML i dansk perspektiv

/ Hans Beier Ommen
ASH24AML Play the Video 09:10
Bjørn Tore Gjertsen

ASH 2024: AML-forskning tar nye steg med CPX-behandling og meninhemmere

/ Bjørn Tore Gjertsen
ASH24AML Play the Video 04:15
Gunnar Juliusson

Swedish Result for Cytarabine Treatment of Secondary AML is Better than the Register Studies

/ Gunnar Juliusson
AML Play the Video 07:05
Hanna Duàn

Genomic Subtypes of AML Determines Sensitivity to NK Cell Cytotoxicity

/ Hanna Duàn
ASH24AML Play the Video 2:36
Gunnar Juliusson

Cytarabine Dose Intensification Improves Survival in Older Patients with AML

/ Gunnar Juliusson
AML Play the Video 08:21

The Development of New Treatment Options within AML Is Slower Than in Other Disease Areas within Hematology

/ BestPractice Nordic
EHA24AML
Nikolaj Nitschke

Functional Characterization for Germline Variants in Patients with MDS and AML

/ Nikolaj Juul Nitschke
EHA24AML Play the Video 03:17

Drug Sensitivity Screening to Guide Clinical Decisions for Hematologic Cancers

/ Sigrid S. Skånland
AMLCLL
Jason Westin

Potential for Targeted and Immune-Facing Therapies for Patients with CNS Lymphoma

/ Jason Westin
ASH23Lymfom Play the Video 01:08

Brænder du for at skrive?

Vil du gerne dele din forskning eller dine kliniske erfaringer med dine kollegaer inden for netop dit speciale? Har du en ide til en artikel, som du gerne vil udgive hos os? Send redaktionen en mail på redaktion@bpno.dk

Send mail til redaktionen
Back to top